Answers are grounded in this paper and cite their sources.
Analyzing barriers impacting payer decisions on pharmaceutical reimbursement, suggesting standards for real-world evidence use.
US payers are interested in incorporating real-world evidence (RWE) into their pharmaceutical coverage and reimbursement decisions. One barrier to using RWE to inform decisions is the lack of standards for RWE assessment and interpretation specific to US payer needs.
No takes yet. Share an insight, caveat, or question.
Lockhart et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: